Trade AstraZeneca ^AZN

AstraZeneca (LON:AZN) Stock Keeps "Buy" Rating at Berenberg Bank

Chemotherapy Group Stuns with Exceptional Performance, Delivering a Crushing Blow to Allist's Global Ambitions

Analyzing Astrazeneca (NYSE:AZN) and Biofrontera (NASDAQ:BFRI) - Daily Political

Head-To-Head Analysis: Vanda Pharmaceuticals (NASDAQ:VNDA) vs. Astrazeneca (NYSE:AZN) - Zolmax

Financial Analysis: Vanda Pharmaceuticals (NASDAQ:VNDA) & Astrazeneca (NYSE:AZN) - Markets Daily

Canandaigua National Bank & Trust Co. Purchases 11,271 Shares of Astrazeneca Plc $AZN

Astrazeneca Plc $AZN Shares Newly Acquired by Canandaigua National Bank & Trust Co. - Stock Observer

AstraZeneca (LSE:AZN) Stock Looks Reasonable Based On Current Earnings

Summit Therapeutics Stock Has The Bull Case Changed After AstraZeneca Backing

Startup Funding News Today, October 7, 2026: Nous Research, Monid, Multiply Labs, Quanfluence & More

Jefferies Financial Group Reaffirms Buy Rating for AstraZeneca (LON:AZN)

AstraZeneca's Etcamah: A Game-Changer in Breast Cancer Treatment Approved in India, ETPharma

How Investors Are Reacting To Daiichi Sankyo Company (TSE:4568) Expanding Datroway's Oncology Combination Program

AstraZeneca (LON:AZN) Stock Rating Reaffirmed as "Buy" by Berenberg Bank

AstraZeneca PLC (LON:AZN) Stock Has Consensus Price Target of £150 - Markets Daily

AstraZeneca CEO Pascal Soriot on Summit ivonescimab combos

Best Manufacturing Stocks To Watch Today - October 6th - Daily Political

Is this under-the-radar FTSE 250 biotech gem set to soar from £5.43 to £13.92?

Philippines vies for Asia clinical research hub | Daily Tribune

AstraZeneca CEO Pascal Soriot on new Boston site: Faster, better development of new products is the hope

AstraZeneca opens $1 billion R&D center in Massachusetts

Park National Corp OH Purchases 67,214 Shares of Astrazeneca Plc $AZN

AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts | Morningstar

Clinical trial experts turn to AI and new partnerships to tackle growing trial complexity

Barclays Sticks to Their Buy Rating for AstraZeneca (AZN)

Meet the UK growth stock that's forecast to climb 35% - and whose boss just bought £7.3m of its shares

DTI, AstraZeneca deepen Philippines clinical | Daily Tribune

COPD trial wins spur broad respiratory hopes

AstraZeneca PLC (LON:AZN) Stock Rated "Moderate Buy" by Sell-Side Brokerages

Astrazeneca (NYSE:AZN) & Redhill Biopharma (NASDAQ:RDHL) Financial Analysis

Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration

AstraZeneca and Daiichi Sankyo Join Summit Therapeutics to Advance Cancer Treatment, ETPharma

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Summit Therapeutics (SMMT), What Is Behind The Fresh Attention?

Daiichi Sankyo, AstraZeneca, Summit Partner On Datroway- Ivonescimab Cancer Studies

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway | Morningstar

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types | Morningstar

AstraZeneca (LON:AZN) Stock Keeps Hold Rating at Deutsche Bank Aktiengesellschaft - Markets Daily

AstraZeneca's (AZN) Hold Rating Reiterated at Deutsche Bank Aktiengesellschaft - Markets Daily

Deutsche Bank Aktiengesellschaft Reaffirms "Hold" Rating for AstraZeneca (LON:AZN) - Markets Daily

AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up

Association of hypertension specialist treatment with blood pressure control in Japanese primary care: The J-DOME study

Urine cell-free RNA for bladder cancer detection and treatment response prediction

AstraZeneca Stocks Drops as $2 Billion Buys an Oncology Option

What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership?

Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial

700,000 Seniors Have Started GLP-1s Through Medicare. Now AstraZeneca Just Moved a Once-Daily Pill Into Phase 3

AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets

AstraZeneca Dealt Latest Loss in Arkansas Drug Discount Case

Drug Repurposing Market - Global Strategic Business Report: Forecasts Growth to $37.3Billion by 2030, Profiling AbbVie, AstraZeneca, Pfizer, Novartis & Johnson & Johnson

Is AstraZeneca (LSE:AZN) Undervalued Following Its New Lung Cancer FDA Filing?

Contrasting Tarsus Pharmaceuticals (NASDAQ:TARS) & Astrazeneca (NYSE:AZN)

Head-To-Head Contrast: Astrazeneca (NYSE:AZN) vs. Tarsus Pharmaceuticals (NASDAQ:TARS) - Stock Observer

Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer

Periarterial nerves along the human hepatic artery: anatomical determinants for cardiometabolic neuromodulation

A $2 Billion Reason Why AstraZeneca Stock Is Down Today

Biotech Stocks On The Move - SLXN, SMMT, IOVA, NTHI

Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment

Summit Therapeutics Stock Rises 7% After AstraZeneca Strategic Investment

Why is Summit Therapeutics share price up today by 22%?

Biotech Pre-Market Movers: SLXN, SMMT Surge; NIVF, QURE Slide

AstraZeneca Invests $2B in Summit for Cancer Drug Dev

AstraZeneca invests $2B in Summit, gaining 'seat at the table' for PD-1/VEGF drug push

Summit agrees to $2 billion AstraZeneca equity investment - Daily Political

Premarket movers: FICO sinks while Summit, AAR and CarMax rise

Summit Therapeutics (SMMT) Shares Surge 15% on AstraZeneca's $2B Deal - Blockonomi

AstraZeneca Invests $2$ in Summit Therapeutics

AstraZeneca to invest $2bn in Summit for ADC combination therapies

Summit soars after $2 billion investment from AstraZeneca for cancer therapies

Astrazeneca Shares Hit Two-Month High After $2Bn Summit Deal

AstraZeneca's $2 Billion Investment in Summit Therapeutics: A Leap Forward in Cancer Treatment, ETPharma

AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows

AstraZeneca's (AZN) Hold Rating Reaffirmed at Deutsche Bank Aktiengesellschaft - Daily Political

AstraZeneca (LON:AZN) Given Hold Rating at Deutsche Bank Aktiengesellschaft - Daily Political

AstraZeneca scales Summit's PD-1xVEGF combos with $2B investment

Summit stock surges on $2 billion AstraZeneca investment

HUTCHMED Seeks FDA Approval For ORPATHYS-TAGRISSO In Resistant Lung Cancer

AstraZeneca Invests $2 Billion In Summit, Expands Cancer Drug Collaboration; Stock Up

Hutchmed says AstraZeneca submits NDA for ORPATHYS+TAGRISSO in NSCLC

Closing Bell Movers: Summit Therapeutics jumps on AstraZeneca investment

Acute Myocardial Infarction Market: Expanding Therapeutic Innovation, Secondary Prevention Strategies, and Emerging Pipeline Therapies to Drive Growth Through 2036 | ABNewswire

Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial

Summit Therapeutics up 15% after AstraZeneca makes $2B equity investment

Summit Therapeutics, AstraZeneca enter clinical collaboration agreement

AstraZeneca makes $2B equity investment in Summit Therapeutics

AstraZeneca (AZN) is Expanding its Oncology Engine. Can New Growth Offset Legacy Pressure?

Summit Therapeutics (SMMT) Secures $2B AstraZeneca Investment, S

Summit shares surge after-hours on $2 billion AstraZeneca equity deal

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics | Morningstar

Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004) | Morningstar

The FDA Calendar to April 2027: 5 Biotech Stocks From the KXCO Biotech Ontology

Insurance coverage lags as cancer science, treatment move forward | News & Features | ArcaMax Publishing

Insurance coverage lags as cancer science, treatment move forward | Health & Fitness | ArcaMax Publishing

AstraZeneca's Pam Cheng's Road to Sustainability Leadership | Sustainability Magazine

Novo Nordisk (0QIU) Receives a Hold from Bank of America Securities

AstraZeneca's IMFINZI-Enfortumab Regimen Wins FDA Priority Review In Bladder Cancer

NIH cuts delayed a cancer trial. Patients lost time they didn't have

Nine pharma chiefs urge action as Europe loses ground to US and China - EU Reporter

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

TEM stock price analysis: Why Tempus AI Stock Up Today?

FTSE 100 index near one-month lows as global sentiment sours

Moderna share price jumps as Oppenheimer upgrades stock

Week ahead: RBA poised to hike?

FTSE 100 Index: London stocks start week sharply lower

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk